Pancreatic cancer is difficult to diagnose at an early stage, with about 80% of patients having local invasion or distant metastasis at the initial consultation. At present, surgical resection remains the only hope for long-term survival in patients with pancreatic cancer. The level of comprehensive treatment of pancreatic cancer has somewhat improved over the past few years. In borderline resectable pancreatic cancer, the use of neoadjuvant therapy may achieve the goal of tumor downstaging, and screening and selecting potential patients for surgery. Proper selection of chemotherapy regimen and appropriate choice of surgery timing can further improve the resection rate of pancreatic cancer, and thereby prolong the survival time in this high-risk population.